三、本员工持股计划已通过工会委员会等组织充分征求了员工意见，拟参与对 象遵循依法合规、自愿参与、风险自担的原则，不存在摊派、强行分配等方式强制 员工参与员工持股计划的情形； 因此，我们同意公司实施第四期员工持股计划（草案），并将第四期员工持股 计划（草案）相关议案提交公司董事会审议。 浙江京新药业股份有限公司 董事会薪酬与考核委员会 2025 年 9 月 29 日 1 浙江京新药业股份有限公司 董事会薪酬与考核委员会关于公司第四期员工持股计划（草案） 相关事项的意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》（以下简称"《证券法》"）、《关于上市公司实施员工持股计划试点的指导意见》 等有关法律、法规以及《浙江京新药业股份有限公司章程》的规定，我们作为浙江 京新药业股份有限公司（以下简称"公司"）董事会薪酬与考核委员会委员，对公 司第四期员工持股计划（草案）相关事项发表如下意见： 一、公司实施第四期员工持股计划（草案）有利于建立和完善员工与股东的利 益共享机制，健全公司长期、有效的激励约束机制，充分调动员工积极性，提高员 工的凝聚力和公司竞争力；同时，有助于公司进一步完善 ...

证券代码：002020 证券简称：京新药业 上海荣正企业咨询服务（集团）股份有限公司 关 于 浙江京新药业股份有限公司 第四期员工持股计划（草案） 之 独立财务顾问报告 2025 年 9 月 | | | | 一、释义 | | --- | | 二、声明………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 4 | | 三、基本假设 | | 四、本员工持股计划的主要内容 ………………………………………………………………………………………………………………………… 6 | | (一) 本员工持股计划的资金来源和股票来源 . | | (二) 本员工持股计划的参加对象及确定标准 . | | (三) 本员工持股计划的持有人名单及分配情况 | | (四)员工持股计划的存续期、持股期限及锁定期 . | | (五) 公司融资时本员工持股计划的参与方式 . | | (六) 本员工持股计划的管理模式……………………………………… ...

浙江京新药业股份有限公司第四期员工持股计划（草案）摘要 证券简称：京新药业 证券代码：002020 浙江京新药业股份有限公司 第四期员工持股计划 （草案）摘要 二零二五年九月 声 明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2/36 浙江京新药业股份有限公司第四期员工持股计划（草案）摘要 风险提示 一、本员工持股计划须经公司股东大会批准后方可实施，后续能否获得公司 股东大会批准尚存在不确定性。 二、有关本员工持股计划的具体参与人数、资金来源、出资规模、实施方案 等属初步方案，本员工持股计划能否最终完成实施，存在不确定性。 三、员工遵循依法合规、自愿参与、风险自担原则参与本员工持股计划。若 员工认购金额较低时，本员工持股计划存在不成立或者低于预计规模的风险。 四、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策，注 意投资风险。 3/36 浙江京新药业股份有限公司第四期员工持股计划（草案）摘要 特别提示 本部分内容中的词语简称与"释义"部分保持一致。 一、《浙江京新药业股份有限公司第四期员工持股计划（草案）》系浙江京 新药业股份有限公司（以下简 ...

Summary of Jin Xin Pharmaceutical Conference Call Company Overview - Jin Xin Pharmaceutical has completed centralized procurement and achieved stable revenue and profit growth by expanding its outpatient market [2][4]. Financial Performance - The projected non-deductible net profit for 2024 is approximately 630 million yuan, with expectations for double-digit growth in the coming years [2][4]. - For 2025, the estimated non-deductible net profit is expected to reach 700 million yuan, with total profit around 800 million yuan, supporting a market capitalization of 10-12 billion yuan [2][4]. Key Products and Innovations - The innovative insomnia drug, Tida Xini, is set to enter the medical insurance system in November 2024, priced higher than similar generic drugs [2][5]. - Tida Xini is expected to achieve sales of 180-200 million yuan in 2025, significantly exceeding market expectations of 500-800 million yuan, with potential to surpass 2 billion yuan in sales in the future, corresponding to a market cap of 6 billion yuan [2][5]. Research and Development - Jin Xin's oral LPA small molecule research is leading globally, currently in deep negotiations with overseas multinational corporations (MNCs) [2][6]. - Based on the valuation of similar transactions, the BD transaction valuation for Jin Xin's oral LPA is estimated to be at least 1.5-2 billion USD, corresponding to a market cap of approximately 10 billion yuan [2][6]. Strategic Direction - Jin Xin Pharmaceutical is committed to innovation and will continue to advance its research pipeline while actively expanding its projects in the psychiatric and neurological fields, enhancing the company's long-term investment value [3][7]. Market Position - The company has stabilized its core business after facing intense competition in centralized procurement during 2020 and 2021, successfully completing procurement for several products [4][5]. - The company’s strategic focus on innovative products and R&D positions it favorably in the pharmaceutical market, with a potential market cap of 30 billion yuan if key strategies are realized [4]. Additional Insights - Tida Xini's short half-life and lack of accumulation effects present significant innovation in the field of psychiatry, particularly for insomnia treatment [5]. - Jin Xin's progress in oral LPA small molecules is notable, being second only to Heng Rui and AstraZeneca in the small molecule sector [6]. This summary encapsulates the key points from the conference call, highlighting Jin Xin Pharmaceutical's financial outlook, product innovations, R&D advancements, and strategic direction.

Market Overview - As of September 24, the Shanghai Composite Index closed at 3853.64 points, with a gain of 0.83%. The Shenzhen Component Index closed at 13356.14 points, up by 1.80%. The ChiNext Index closed at 3185.57 points, increasing by 2.28% [1]. Trading Activity - A total of 2309 stocks saw an increase in average transaction volume, with 57 stocks experiencing a rise of over 50% in average transaction volume. Conversely, 2250 stocks reported a decrease in average transaction volume [1]. - Notable stocks with significant increases in average transaction volume include ST Jinggu, *ST Yatai, and Shibei Gaoxin, which showed substantial growth [1]. Individual Stock Performance - The following stocks had the highest increases in average transaction volume on September 24: - ST Jinggu: 5.00% increase, average transaction volume of 4012 shares, up by 248.10% - *ST Yatai: 5.04% increase, average transaction volume of 5621 shares, up by 159.79% - Shibei Gaoxin: 9.98% increase, average transaction volume of 2946 shares, up by 158.79% [1]. Trading Volume and Transaction Count - The stocks with the highest increase in transaction count include: - Heertai: 1.47% increase, 453,845 transactions, up by 7936.92% - Dazhong Public Utilities: 4.79% increase, 278,574 transactions, up by 2732.19% - ST Chuangyi: -4.13% decrease, 37,426 transactions, up by 2449.46% [2]. Stocks with Significant Growth - The following stocks had both average transaction volume and transaction count increase by over 50%: - *ST Yatai: 5.04% increase, average transaction volume of 5621 shares, up by 159.79%, with 2238 transactions, up by 1273.01% [3]. - Other notable stocks include: - Yangyuan Beverage: 9.98% increase, average transaction volume of 785 shares, up by 104.84%, with 17,973 transactions, up by 118.81% [4].

Core Points - The company announced the nomination of candidates for the ninth board of directors, including both non-independent and independent directors [1] Group 1 - The board of directors has proposed the nomination of five non-independent director candidates: Lü Gang, Wang Nengneng, Hong Yunfei, Lü Jiaqing, and Li Bixiang [1] - The board has also nominated three independent director candidates: Lei Ying, Xu Pan, and Huang Tao [1]

Core Viewpoint - The article provides insights into the latest perspectives and recommendations for the pharmaceutical sector, emphasizing the importance of historical context in analyzing the industry and individual stocks [4]. Group 1: Pharmaceutical Sector Insights - The research team at Guotai Junan Securities specializes in analyzing the global pharmaceutical industry over 40 years and the Chinese pharmaceutical industry over 20 years, focusing on a comprehensive view of industry development to identify investment opportunities [4]. - Key discussions are scheduled for various segments of the pharmaceutical industry, including medical devices, innovative drugs, and CXO & upstream sectors, with prominent analysts leading these discussions [5][6][7]. Group 2: Upcoming Events and Recommendations - A series of conference calls are planned from September 22 to September 26, covering different aspects of the pharmaceutical sector, with notable analysts presenting their insights and recommendations [5][6][7]. - The focus will be on recent key recommendations and deep dives into specific stocks, highlighting the ongoing analysis and updates in the pharmaceutical landscape [7].

Group 1 - The company, Jingxin Pharmaceutical, announced the convening of its 17th board meeting on September 24, 2025, to review governance system proposals [1] - For the first half of 2025, Jingxin Pharmaceutical's revenue composition was as follows: finished drugs accounted for 58.28%, raw materials for 22.44%, medical devices for 17.32%, and other businesses for 1.95% [1] - As of the report date, Jingxin Pharmaceutical's market capitalization was 18.6 billion yuan [1]

浙江京新药业股份有限公司 外汇套期保值业务管理制度 （已经 2025 年 9 月 24 日公司第八届董事会第十七次会议审议通过） 第一章 总则 第一条 为了进一步规范浙江京新药业股份有限公司（以下称"公司"）的 外汇套期保值业务，有效防范和降低汇率波动给公司经营造成的风险，保证汇率 风险的可控性，根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳 证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》及《公司章程》等的有关规定，结合公司具体实际，特 制定本制度。 第二条 外汇套期保值业务是指为满足正常生产经营需要，在银行办理的规 避和防范汇率或利率风险的外汇套期保值业务，包括远期结售汇、外汇掉期、外 汇互换、外汇期权业务及其他外汇衍生交易业务。 第三条 本制度适用于公司、全资及控股子公司的远期结售汇套期保值业务， 全资及控股子公司进行远期结售汇套期保值业务视同上市公司远期结售汇业务。 但未经公司同意，公司下属全资及控股子公司不得操作该业务。 第九条 公司年度外汇套期保值计划经董事会或股东会审议批准后才能实 施，具体决策权限为: 第二章 外汇套期保值业务操作规 ...

（已经2025年9月24日公司第八届董事会第十七次会议审议通过） 第一章 总则 第一条 为规范浙江京新药业股份有限公司（以下简称"公司"）董事、高级 管理人员离职相关事宜，确保公司治理结构的稳定性和连续性，维护公司及股东 的合法权益，公司根据《中华人民共和国公司法》（以下简称"《公司法》"）、 浙江京新药业股份有限公司 董事、高级管理人员离职管理制度 《深圳证券交易所股票上市规则》《上市公司章程指引》等法律法规、规范性文 件及《浙江京新药业股份有限公司章程》（以下简称"《公司章程》"）的有关规 定，结合公司实际情况，制定本制度。 第二条 本制度适用于公司董事（含独立董事）、高级管理人员因任期届满、 辞职、被解除职务或其他原因离职的情形。 第二章 离职情形与程序 第三条 公司董事和高级管理人员可以在任期届满以前辞职，董事和高级 管理人员辞职应当向公司提交书面辞职报告，辞职报告中应说明辞职原因，公 司收到辞职报告之日辞职生效，公司将在两个交易日内披露有关情况。 第四条 如存在下列情形，在改选出的董事就任前，原董事仍应当依照法律、 行政法规、部门规章和《公司章程》的规定，继续履行董事职责，但存在相关法 规另有规定的 ...